Literature DB >> 26474373

Association of Low B Cell Count and IgG Levels With Infection, and Poor Vaccine Response With All-Cause Mortality in an Immunosuppressed Vasculitis Population.

Matthew David Morgan1, Alex Richter1, Samer Al-Ali1, Julia Flint1, Constantina Yiannakis1, Mark Drayson1, David Goldblatt2, Lorraine Harper1.   

Abstract

OBJECTIVE: Patients with systemic vasculitis (SV) have an increased risk of all-cause mortality, often due to infection, compared to the healthy population. We investigated whether humoral response to vaccination and biomarkers of immune dysfunction were associated with infection and death.
METHODS: Patients with SV in remission were vaccinated with pneumococcal 7-valent conjugate, Haemophilus influenzae type b, and meningococcal group C conjugate vaccine and meningococcal polysaccharide groups A, C, Y, and W135 vaccines. Total IgG and antibody titers against specific antigens and lymphocyte subset analysis were performed before vaccination. Postvaccination antibody titers were measured at 4 weeks and 2 years, from which an antibody response score was calculated. Infections and death following vaccination were collected prospectively following vaccination.
RESULTS: A total of 92 patients were safely vaccinated with no increase in disease relapse, median followup 4.6 years (interquartile range [IQR] 3.6-4.8 years). Eighteen patients died at a median of 2 years and the overall infection rate was 0.4 (IQR 0.2-1.3) infections/patient/year. Reduced serum IgG, B cell count, and CD4+ cell counts predicted poor vaccine response and infection but not death. The response rates to individual vaccine antigens was highly variable, with a median response rate of 46% (IQR 39-58%) of patients responding to each individual antigen. Vaccine response, age, and reduced renal function were independent predictors of all-cause mortality in multivariate analysis.
CONCLUSION: Total IgG and B cell counts predict infection and response to vaccination. Vaccination in patients with SV in remission is safe and the response predicts all-cause mortality. Vaccine response is a surrogate marker of immune system health.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26474373     DOI: 10.1002/acr.22757

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  5 in total

Review 1.  Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.

Authors:  Catherine King; Lorraine Harper
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-11-13

2.  Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Authors:  Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-09

3.  Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.

Authors:  Nimita Dave; Sathej Gopalakrishnan; Sven Mensing; Ahmed Hamed Salem
Journal:  Clin Transl Sci       Date:  2019-08-07       Impact factor: 4.689

Review 4.  Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.

Authors:  Giuseppe Murdaca; Giovanni Noberasco; Dario Olobardi; Claudio Lunardi; Matteo Maule; Lorenzo Delfino; Massimo Triggiani; Chiara Cardamone; Devis Benfaremo; Gianluca Moroncini; Angelo Vacca; Nicola Susca; Sebastiano Gangemi; Paola Quattrocchi; Laura Sticchi; Giancarlo Icardi; Andrea Orsi
Journal:  Vaccines (Basel)       Date:  2021-12-02

5.  Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Dimitrios Chanouzas; Michael Sagmeister; Sian Faustini; Peter Nightingale; Alex Richter; Charles J Ferro; Matthew David Morgan; Paul Moss; Lorraine Harper
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.